Cssil adds Exelixis (EXEL) to its portfolio

Exelixis (EXEL) : Cssil added new position in Exelixis during the most recent quarter end. The investment management firm now holds 615,075 shares of Exelixis which is valued at $10,308,657 , the company said in a statement filed on Nov 14, 2016 with the SEC.Exelixis makes up approximately 1.04% of Cssil’s portfolio.

Other Hedge Funds, Including , Gsa Capital Partners Llp boosted its stake in EXEL in the latest quarter, The investment management firm added 22,336 additional shares and now holds a total of 37,318 shares of Exelixis which is valued at $625,450. Exelixis makes up approx 0.03% of Gsa Capital Partners Llp’s portfolio. Cibc World Markets added EXEL to its portfolio by purchasing 118,934 company shares during the most recent quarter which is valued at $1,213,127. Exelixis makes up approx 0.01% of Cibc World Markets’s portfolio.Public Employees Retirement Association Of Colorado reduced its stake in EXEL by selling 6,442 shares or 11.14% in the most recent quarter. The Hedge Fund company now holds 51,395 shares of EXEL which is valued at $555,580. Jennison Associates added EXEL to its portfolio by purchasing 500,000 company shares during the most recent quarter which is valued at $5,405,000. Exelixis makes up approx 0.01% of Jennison Associates’s portfolio.Nationwide Fund Advisors boosted its stake in EXEL in the latest quarter, The investment management firm added 42,878 additional shares and now holds a total of 188,996 shares of Exelixis which is valued at $2,177,234. Exelixis makes up approx 0.01% of Nationwide Fund Advisors’s portfolio.

Exelixis opened for trading at $16.75 and hit $16.975 on the upside on Monday, eventually ending the session at $16.96, with a gain of 1.25% or 0.21 points. The heightened volatility saw the trading volume jump to 65,66,312 shares. Company has a market cap of $4,858 M.

On the company’s financial health, Exelixis reported $-0.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Nov 3, 2016. Analyst had a consensus of $-0.13. The company had revenue of $62.19 million for the quarter, compared to analysts expectations of $45.48 million. The company’s revenue was up 531.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.22 EPS.

Many Wall Street Analysts have commented on Exelixis. Deutsche Bank Initiated Exelixis on Nov 3, 2016 to “Buy”, Price Target of the shares are set at $17.Exelixis was Upgraded by Piper Jaffray to ” Overweight” on Oct 10, 2016. Company shares were Reiterated by Stifel on Sep 15, 2016 to “Buy”, Firm has raised the Price Target to $ 15 from a previous price target of $12 .

Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive metastatic medullary thyroid cancer (MTC) in the United States. The Company’s other programs include metastatic renal cell carcinoma (mRCC) a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888 a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Exelixis - Is it time to Sell?

Top Brokerage Firms are advising their investors on Exelixis. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.